Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1

Interventions

fludarabine phosphate 5Cyclophosphamide 4Whole-Body Irradiation 3Cyclosporine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3fludarabine 2Stem Cell Transplantation 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2Hydroxyurea 2Busulfan 2Antilymphocyte Serum 2ruxolitinib 1nelarabine 1fresolimumab 1arsenous acid 1Watchful Waiting 1Thiotepa 1Tetradecanoylphorbol Acetate 1Surveys and Questionnaires 1RG7388 1Phlebotomy 1Oxycodone 1Observation 1Nivolumab 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Moxifloxacin 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Polycythemia Vera × arsenous acid × Clear all
NCT01014546 2022-07-22

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Roswell Park Cancer Institute

Phase 1 Terminated
5 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡